<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01042873</url>
  </required_header>
  <id_info>
    <org_study_id>0355-09-HMO-CTIL</org_study_id>
    <secondary_id>0355-09-HMO</secondary_id>
    <nct_id>NCT01042873</nct_id>
  </id_info>
  <brief_title>The Hemodynamic Response to Prolonged Dobutamine Infusion</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A decrease in the response of beta 1 adrenergic receptors to agonists (desensitization) is
      thought to play a major role in the pathogenesis of diseases such as congestive heart
      failure. However, currently, there is no in vivo model that will enable us to measure
      desensitization of the hemodynamic responses to beta 1 adrenergic receptors in vivo.

      Our hypothesis is that constant 3 hours intravenous infusion of the selective beta1
      adrenergic receptor agonist dobutamine will result in gradual decline in hemodynamic
      responses to dobutamine over time.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Heart rate</measure>
    <time_frame>3 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure</measure>
    <time_frame>3 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Healthy</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Intravenous dobutamine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>3 hours infusion of dobutamine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3 hours intravenous dobutamine</intervention_name>
    <description>Intravenous dobutamine will be infused during 3 hours. At the first and last 0.5 hors of infusion dose will be increased gradually, while in the middle 2 hours dose will remain constant.</description>
    <arm_group_label>Intravenous dobutamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy subjects

        Exclusion Criteria:

          -  consumption of any medications during the 2 weeks prior to the study

          -  history of chest pain or tachycardia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hadassah University Hospital</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mordechai Muszkat, MD</last_name>
      <phone>972-2-6777335</phone>
      <email>muszkatm@hadassah.org.il</email>
    </contact>
    <investigator>
      <last_name>Mordechai Muszkat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Bruck H, Leineweber K, Temme T, Weber M, Heusch G, Philipp T, Brodde OE. The Arg389Gly beta1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity. J Am Coll Cardiol. 2005 Dec 6;46(11):2111-5. Epub 2005 Nov 4.</citation>
    <PMID>16325050</PMID>
  </reference>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2010</study_first_submitted>
  <study_first_submitted_qc>January 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2010</study_first_posted>
  <last_update_submitted>July 3, 2011</last_update_submitted>
  <last_update_submitted_qc>July 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2011</last_update_posted>
  <responsible_party>
    <name_title>Mordechai Muszkat, MD</name_title>
    <organization>Hadassah-Hebrew University Medical Center</organization>
  </responsible_party>
  <keyword>Desensitization</keyword>
  <keyword>beta adrenergic receptors</keyword>
  <keyword>Healthy subjects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dobutamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

